900909:SSEShanghai Huayi Group Corporation Ltd. Class B Analysis
Data as of 2026-07-27 - not real-time
$0.49
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Shanghai Huayi Group trades at ¥0.486, sitting just above the calculated support of ¥0.481 and below both the 20‑day (¥0.496) and 50‑day (¥0.493) simple moving averages, indicating a short‑term price weakness. The RSI of 41 points to a mildly oversold condition, while the MACD histogram remains negative, reinforcing a bearish momentum bias. Despite the price pressure, the stock boasts an attractive dividend yield of **5.04%** and a low price‑to‑book ratio of **0.31**, suggesting a significant margin of safety relative to its book value. The company’s beta of 0.19 signals very low systematic risk, and its 30‑day volatility of 17% is modest for a basic‑materials name.
Fundamentally, revenue growth is sluggish at 1.6% and profit margins are thin (gross 7.5%, net 1.2%), with ROE barely above 1.9%, which limits upside potential. Nevertheless, a strong cash position (¥16.5 bn) more than covers total debt (¥12.6 bn), and a payout ratio of 66% appears sustainable given current free cash flow. The chemical sector’s cyclical nature and China‑centric exposure introduce medium‑level regulatory and geographic risks, but the stock’s liquidity is constrained by decreasing trading volume. Overall, the combination of a deep discount to book, robust dividend, and low beta makes the stock appealing for value‑oriented investors, while the weak earnings profile tempers expectations for rapid price appreciation.
Fundamentally, revenue growth is sluggish at 1.6% and profit margins are thin (gross 7.5%, net 1.2%), with ROE barely above 1.9%, which limits upside potential. Nevertheless, a strong cash position (¥16.5 bn) more than covers total debt (¥12.6 bn), and a payout ratio of 66% appears sustainable given current free cash flow. The chemical sector’s cyclical nature and China‑centric exposure introduce medium‑level regulatory and geographic risks, but the stock’s liquidity is constrained by decreasing trading volume. Overall, the combination of a deep discount to book, robust dividend, and low beta makes the stock appealing for value‑oriented investors, while the weak earnings profile tempers expectations for rapid price appreciation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price hovering near technical support
- Bearish MACD and decreasing volume
- Dividend yield provides cushion
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- Undervalued price relative to book value
- Sustainable dividend payout
- Strong cash balance offsetting debt
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Low beta and defensive dividend profile
- Potential for margin improvement in chemicals sector
- Long‑term discount to intrinsic (DCF) valuation
Key Metrics & Analysis
Financial Health
Revenue Growth1.60%
Profit Margin1.22%
P/E Ratio12.2
ROE1.92%
ROA0.03%
Debt/Equity40.58
P/B Ratio0.3
Op. Cash Flow$6.5B
Free Cash Flow$1.4B
Technical Analysis
TrendNeutral
RSI41.2
Support$0.48
Resistance$0.52
MA 20$0.50
MA 50$0.49
MA 200$0.52
MACDBearish
VolumeDecreasing
Fear & Greed Index89.91
Valuation
Fair Value$11.11
GradeUndervalued
TypeValue
Dividend Yield5.04%
Risk Assessment
Beta0.19
Volatility17.02%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.